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Abstract
The epidemiology of multimorbidity, or multiple chronic conditions (MCCs), is one of the research priority areas 
of the U.S. Department of Health and Human Services (HHS) by its Strategic Framework on MCCs. A conceptual 
model addressing methodological issues leading to a valid measurement of the prevalence rates of MCCs has been 
developed and applied in descriptive epidemiological studies. Comparing these results with those from prevalence 
studies performed earlier and in other countries is hampered by methodological limitations. Therefore, this paper 
aims to put the size and patterns of MCCs in the USA, as established within the HHS Strategic Framework on 
MCCs, in perspective of the fi ndings on the prevalence of MCCs in other countries. General common trends can be 
observed: increasing prevalence rates with increasing age, and multimorbidity being the rule rather than the excep-
tion at old age. Most frequent combinations of chronic diseases include the most frequently occurring single chronic 
diseases. New descriptive epidemiological studies will probably not provide new results; therefore, future descriptive 
studies should focus on the prevalence rates of MCCs in subpopulations, statistical clustering of chronic conditions, 
and the development of the prevalence rates of MCCs over time. The fi nding of common trends also indicates the 
necessary transition to a next phase of MCC research, addressing the quality of care of patients with MCCs from an 
organizational perspective and with respect to the content of care.
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Introduction
The aging of mankind, which we are currently witnessing 
all over the world, is unprecedented in human history. Life 
expectancy breaks records, and a 100th birthday is no lon-
ger a rare event. The reverse side of this – in many respects 
successful – development is the increasing number of 
people with chronic diseases. The occurrence of many 
chronic diseases is related to increasing age, which can 
often be explained by long-lasting exposure to risk factors 
(e.g. smoking, overweight, physically burdensome labor). 
In 1986, Olshansky and Ault fi rst predicted this develop-
ment by announcing the entry into the “Fourth Stage of 
the Epidemiologic Transition: The Age of Delayed Degen-
erative Diseases” [1], calling for “new ways of thinking 
about aging, disease, morbidity, mortality, and certainly 
how life will be lived in advanced ages in the very near 
future.” However, at that time, Olshansky and Ault did not 
specifi cally predict the increasing number of people with 
multiple chronic conditions (MCCs), which has received 
increasing attention over the last few decades, and which 
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represents a major challenge for public health, healthcare, 
and social care as recognized by the U.S. Department of 
Health and Human Services (HHS) by its Strategic Frame-
work on Multiple Chronic Conditions [2]. Although the 
relevance of MCCs, or comorbidity, was demonstrated by 
Feinstein back in 1970 [3], the attention to MCCs has 
only increased in the last decade when healthcare pro-
fessionals became aware that many people who visited 
them daily for the management of their multiple chronic 
diseases did not resemble the “model” patients with a 
single chronic disease who were included in the random-
ized clinical trials to establish the evidence for effective 
treatment and management [4]. This also signifi es the end 
of what one could call the fi rst wave of evidence-based 
medicine: effective treatments have been established for 
many chronic diseases; however, the effectiveness of treat-
ment has been established in homogeneous single-disease 
study populations in whom the existence of other chronic 
conditions is usually an exclusion criterion [5].
Awareness of the relevance of MCCs initially led to 
the establishment of the size, patterns, and determinants 
of MCCs by descriptive epidemiological research. Many 
researchers from all over the world performed such analy-
ses [6], often by using existing administrative or clinical 
databases. In addition, within the HHS Strategic Frame-
work on MCCs, analyses have been published recently on 
the epidemiology of MCCs across different settings in US 
healthcare [7].
Insight into the size and patterns of MCCs in differ-
ent settings is necessary for the development of preventive 
and management strategies, and for prioritizing studies to 
establish evidence for effective treatment of patients with 
MCCs. This paper aims to put the size and patterns of 
MCCs in the USA, as established within the HHS Strate-
gic Framework on MCCs, in perspective of the fi ndings 
on the prevalence of MCCs in other countries. This 
broader perspective will provide insight into the general-
izability of fi ndings at national levels.
MCC prevalence rates
Valid comparisons of the prevalence rates of multimor-
bidity require a rigorous methodological approach, with 
unequivocal defi nitions, and inclusion criteria for exist-
ing data or strict rules for collection of new data. Several 
authors have addressed the methodological challenges in 
providing the MCC prevalence rates to be comparable 
with other studies. Criteria for comparability of the MCC 
prevalence rates include commonality in: (1) the defi nition 
of chronicity; (2) the level at which chronic conditions 
are defi ned (e.g. transient ischemic attack or cerebrovas-
cular disease); (3) the number of chronic conditions under 
study; (4) the defi nition of multimorbidity; and (5) the 
study population, healthcare setting, or data source (e.g. 
administrative data, clinical databases, or population sur-
veys) [8–10]. Within the HHS Strategic Framework on 
MCCs, a conceptual model has been developed which 
addresses most of these criteria [11].
The two most recent systematic reviews on prevalence 
studies on multimorbidity [8,9] had to deal with the 
heterogeneity of the performed studies. The prevalence 
study performed within the HHS Strategic Framework 
on MCCs [10] applied their own conceptual model [11]. 
All of these studies had the defi nition of multimorbidity 
in common: two or more chronic conditions in the same 
person. The results of these prevalence studies are summa-
rized in Table 1 [8–10,12–29]. This table shows the wide 
variation in the prevalence rates of multimorbidity as can 
be expected from heterogeneous data sources. However, 
there is a clear and consistent trend towards higher preva-
lence rates at older age. Moreover, almost all studies show 
that at advanced age, multimorbidity is the rule rather 
than the exception.
MCC patterns
Some studies [e.g. 10], and the study performed within 
the U.S. HHS Strategic Framework on MCCs [29], have 
paid attention to the pattern of MCCs, i.e. which chronic 
conditions often co-occur. These studies all provide the 
same consistent results, which are highly predictable by the 
prevalence rates of the most frequently occurring single 
chronic conditions. The fi ve most prevalent combina-
tions of two chronic conditions (“dyads”) usually include 
hypertension, (osteo)arthritis, ischemic heart disease, 
diabetes mellitus, with depression and cancer occurring 
more prominently in dyads of chronic conditions at older 
age. Although the comparability of studies on patterns of 
MCCs will highly depend on the level at which chronic 
conditions are defi ned, this does not seem to affect the 
patterns of dyads of chronic conditions.
Next phase in MCC research
These global comparisons between the MCC prevalence 
rates established in the USA and abroad and the patterns 
of MCCs led to the conclusion that new descriptive 
epidemiological studies will probably not provide sig-
nifi cantly different results. This does not mean that these 
types of studies should no longer be undertaken. There are 
still many valid reasons for continuing in-depth descrip-
tive studies, e.g. in specifi c subpopulations, defi ned by 
sociodemographic (e.g. ethnic, socioeconomic), medical 
(diseases), or functional (disability) characteristics. Stud-
ies into (statistical) clustering of diseases, showing higher 
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Table 1 Prevalence of multiple chronic conditions (MCCs) from studies included in systematic reviews outside of the USA and a study performed 
within the U.S. Health and Human Services Strategic Framework on MCCs.
Source  Country  Study population, age 
(years)
 Number of chronic conditions 
under study
 Age (years) and 
prevalence of MCC
Studies cited in Fortin et al., 2012 [8] 
and/or Marengoni et al., 2011 [9]
    
 van den Akker et al., 1998 [12]  Netherlands  General population, all 
ages
 335  80+: 74% (males), 
80% (females)
 Britt et al., 2008 [13]  Australia  General practitioner 
patients, all ages
 18  75+: 83%
 Cazale and Dimitru, 2008 [14]  Canada  General population, 12+  7  12–19: <1%
20–24: 1%
25–44: 2%
45–64: 15%
65–79: 39%
80+: 49%
 Fuchs et al., 1998 [15]  Israel  General population, 
75–94
 14  65%
 Fortin et al., 2005 [16]  Canada  Residents, 18+  All diagnoses  65+: 98%
 Kadam et al., 2007 [17]  UK  Visitors of general 
practitioners, 50+
 185  81%
 Loza et al., 2009 [18]  Spain  Living in community, 
20+
 All diagnoses  20+: 30%
 MacLeod et al., 2004 [19]  UK  General population, 18+  8  30%
 Marengoni et al., 2008 [20]  Sweden  Living in community 
and institutions, 78+
 All chronic conditions  78+: 55%
 Menotti et al., 2001 [21]  Finland, 
Netherlands, 
Italy
 General population, 
65–84, males
 7  23% (Finland)
13% (Netherlands)
15% (Italy)
 Minas et al., 2010 [22]  Greece  Visitors of primary 
health care centers, 14+
 All chronic diseases  54–75: 23%
 Nagel et al., 2008 [23]  Germany  General population, 
50–75
 13  67%
 Naughton et al., 2006 [24]  Ireland  General population, all 
ages
 9  60%
 Rapoport et al., 2004 [25]  Canada  General population, 20+  22  20–39: 11%
40–59: 26%
60–79: 55%
80+: 64%
 Schellevis et al., 1993 [26]  Netherlands  General population, all 
ages
 5  <65: 0.3%
65+: 3.6%
 Schram et al., 2008 [10]  Netherlands  General population, 55+  Depending on setting: 12–13 
(population setting); 68–83 (listed 
patients in general practices)
 55+: 56–72%
 Uijen and van de Lisdonk, 2008 [27]  Netherlands  General population, all 
ages
 All chronic diseases  65–74: 30%
75+: 55%
 Walker, 2007 [28]  Australia  General population, 20+  All long-lasting conditions  70+: 85%
    
Ward et al., 2013 [29]  USA  General population, 18+  10  18–44: 7% (males); 
9% (females)
45–64: 33% (males); 
35% (females)
65+: 63% (males); 
62% (females)
prevalence rates of combinations of chronic diseases than 
can be expected by chance, may provide clues for further 
exploring etiological factors [30]. Moreover, the develop-
ment of MCCs over time needs to be monitored. Such 
studies will provide clues for preventing or delaying the 
occurrence of MCCs, and they will support healthcare 
planning by demonstrating which patients are in highest 
need of care.
However, we must also acknowledge that the body of 
knowledge about the epidemiology of MCCs is nowadays 
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suffi ciently large to take a next step by initiating studies 
addressing the quality of care for patients with MCCs. The 
U.S. HHS Strategic Framework on MCCs took up this 
challenge by prioritizing research into both the organiza-
tion and the content of healthcare for patients with MCCs 
[2]. Two recently published systematic reviews from out-
side the USA showed that there is no evidence for any 
care intervention to be effective for patients with MCCs 
[31,32]. This calls for further development and evaluation 
of, for example, case-management programs or programs 
involving geriatric expertise. Regarding the content of 
care, inclusion of patients with MCCs in clinical tri-
als should be facilitated, parallel to the development of 
methodologies to deal with heterogeneity. In addition, the 
impossibility of developing clinical guidelines for all pos-
sible combinations of diseases should be acknowledged, 
leading to priorities being set. Criteria for priority setting 
could be the level of potential risks for interactions or 
contradictions between clinical guidelines for the separate 
chronic conditions. The development and evaluation of 
effective care programs for patients with MCCs represents 
an even bigger challenge because programs will have to be 
tailored to national healthcare systems regarding both the 
organization and content of care.
Concluding remarks
The aim of this paper was to put the size and patterns of 
MCCs in the USA, as established within the HHS Strate-
gic Framework on MCCs, into perspective of the fi ndings 
on the prevalence of MCCs in other countries. Although 
the comparability of descriptive epidemiological studies is 
hampered by many methodological pitfalls, general trends 
can be observed in studies performed in populations all over 
the world: an increasing prevalence of MCCs with age, and 
MCCs at older age being the rule rather than the exception. 
Moreover, as can been expected, the highest prevalence rates 
of combinations of diseases is determined by the prevalence 
rate levels of the separate diseases. Further descriptive studies 
should go into more depth, especially by studying MCCs in 
different subpopulations. These consistent fi ndings call for 
a next phase in MCC research, focusing on the quality of 
care for patients with MCCs, both from an organizational 
perspective and in terms of the content of care.
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